TUCSON, AZ--(Marketwire - October 18, 2012) - HTG Molecular Diagnostics
, will unveil the EDGE system at the AMP conference in Long Beach, October 25 - 27, 2012. The EDGE system is the first fully-automated instrumentation designed for clinical and research laboratories that offers nucleic acid extraction-free gene expression results from FFPE tissue and a variety of other sample types. The EDGE system is the most advanced automated innovation for rapid, accurate, and reproducible mRNA and miRNA measurement to date. Developed under strict ISO 13485:2003 standards, the EDGE system's barcode-driven template or custom User Select protocols allow multiplexing of up to 47 genes per well using less than a single 5 µm section of FFPE tissue. It eliminates the time-consuming and complex qPCR processes of extraction, amplification, and labeling and can deliver up to 1,500 answers per 24-hour cycle.
"The launch of the EDGE system will mark an industry shift in workflow optimization and therefore a significant and necessary move toward more accessible and accurate answers for laboratorians and patients," states TJ Johnson, CEO of HTG Molecular Diagnostics. "When fully integrated into a laboratory setting, the EDGE system can deliver up to 7000 answers from any sample type per work-week. It is the simple, walk-away automated solution to the 'Tissue Issue,' needing to do more with increasingly smaller samples, many laboratories encounter. The EDGE system derives and reports quantifiable results from a minimal amount of even old or degraded FFPE tissue samples."
HTG Molecular Diagnostics will present the EDGE system at booth 244 in the Long Beach Convention Center during the AMP conference. The organization will also present a Corporate Workshop: The Tissue Issue; Standardizing Targeted Gene Expression Testing in FFPE Tissue, at 2:00 p.m., October 24, in room 102 of the Long Beach Convention Center. Presenters will include TJ Johnson, HTG Molecular Diagnostics President and CEO; Vijay Modur, M.D., Ph.D., HTG Molecular Diagnostics CMO; and Bruce McManus, M.D. Ph.D., FRSC, FCAHS, Director, NCE CECR Centre of Excellence for Prevention of Organ Failure.
ABOUT HTG MOLECULAR DIAGNOSTICS:
HTG Molecular Diagnostics is a privately held company providing products for gene expression profiling, miRNA, and mRNA measurement for clinical research, companion diagnostic and prognostic applications in oncology. The company's qNPA molecular technology platform is well-suited for reliably detecting changes in gene expression levels especially from formalin-fixed, paraffin-embedded (FFPE) tissue. Additional information is available at www.htgmolecular.com.
ABOUT AMP CONFERENCE
The Association for Molecular Pathology (AMP) 2012 Annual Meeting on Genomic Medicine is targeted to clinical practitioners, research scientists, medical education professionals, and students and postdoctoral fellows with an interest in gaining a basic and/or advanced understanding of diagnostic, prognostic, and therapeutic approaches in the areas of hematopathology (leukemias, lymphomas, lymphoproliferative disorders), solid tumors and soft tissue tumors, infectious diseases (viral, bacterial, fungal, parasitic), and inherited diseases, with the goal of improving patient care, improving clinical practice, and enabling constructive interactions with pathologists, other health care practitioners, and laboratory directors and technologists. Visit www.AMP.org for more information.